Invasive neuroendocrine carcinoma of the breast: A distinctive subtype of aggressive mammary carcinoma

Cancer

Volumn 116, Issue 19, 2010, Pages 4463-4473

  Wei, Bing ^a   Ding, Tian ^b   Xing, Yan ^b   Wei, Wei ^b   Tian, Zhen ^c   Tang, Feng ^d   Abraham, Susan ^b   Nayeemuddin, Khazi ^b   Hunt, Kelly ^b   Wu, Yun ^b  

^a SICHUAN UNIVERSITY   (China)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

^d FUDAN UNIVERSITY   (China)

Author keywords

Breast; Ductal carcinoma; Endocrine carcinoma; Invasive carcinoma; Neuroendocrine carcinoma

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BREAST CARCINOMA; BREAST NEUROENDOCRINE CARCINOMA; CANCER GROWTH; CANCER RECURRENCE; CANCER SIZE; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DISTANT METASTASIS; FEMALE; FOLLOW UP; HUMAN; INVASIVE CARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MENOPAUSE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL TIME; TREATMENT OUTCOME; TREATMENT RESPONSE; BREAST TUMOR; CARCINOMA; CASE CONTROL STUDY; MIDDLE AGED; NEOPLASM; PATHOLOGY; RECURRENT DISEASE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, NEUROENDOCRINE; CASE-CONTROL STUDIES; FEMALE; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASMS, HORMONE-DEPENDENT; PROGNOSIS; RECURRENCE; TREATMENT OUTCOME;

EID: 77957582722     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25352     Document Type: Article

References (24)

1. Feyrter F, Hartmann G. On the carcinoid growth form of the carcinoma mammae, especially the carcinoma solidum (Gelatinosum) mammae. Frankf Z Pathol. 1963;73:24-39.
2. Cubilla AL, Woodruff JM. Primary carcinoid tumor of the breast: a report of 8 patients. Am J Surg Pathol. 1977;1:283-292. (Pubitemid 9086644)
3. Fisher ER, Palekar AS. Solid and mucinous varieties of so-called mammary carcinoid tumors. Am J Clin Pathol. 1979;72:909-916.
4. Azzopardi JG, Muretto P, Goddeeris P, Eusebi V, Lauweryns JM. "Carcinoid" tumours of the breast: the morphological spectrum of argyrophil carcinomas. Histopathology. 1982;6:549-569.
5. Papotti M, Macri L, Finzi G, Capella C, Eusebi V, Bussolati G. Neuroendocrine differentiation in carcinomas of the breast: a study of 51 cases. Semin Diagn Pathol. 1989;6:174-188. (Pubitemid 19132528)
6. Rosen PP, Oberman HA. Tumors of the mammary gland. In: Atlas of Tumor Pathology. Washington, DC: AFIP Press; 1993:236-240.
7. Maluf HM, Koerner FC. Solid papillary carcinoma of the breast. A form of intraductal carcinoma with endocrine differentiation frequently associated with mucinous carcinoma. Am J Surg Pathol. 1995;19:1237-1244.
8. Miremadi A, Pinder SE, Lee AH, et al. Neuroendocrine differentiation and prognosis in breast adenocarcinoma. Histopathology. 2002;40:215-222. (Pubitemid 34227111)
9. Sapino A, Righi L, Cassoni P, Papotti M, Gugliotta P, Bussolati G. Expression of apocrine differentiation markers in neuroendocrine breast carcinomas of aged women. Mod Pathol. 2001;14:768-776. (Pubitemid 33069835)
10. Tavassoli FA, Devilee P. Pathology and genetics. In: Tumors of the Breast and Female Genital Organs. WHO Classification of Tumors Series. Lyon, France: IARC Press; 2003: 32-34.
11. Zekioglu O, Erhan Y, Ciris M, Bayramoglu H. Neuroendocrine differentiated carcinomas of the breast: a distinct entity. Breast. 2003;12:251-257. (Pubitemid 36944151)
12. Rovera F, Masciocchi P, Coglitore A, et al. Neuroendocrine carcinomas of the breast. Int J Surg. 2008;6(suppl 1):S113-S115.
13. Makretsov N, Gilks CB, Coldman AJ, Hayes M, Huntsman D. Tissue microarray analysis of neuroendocrine differentiation and its prognostic significance in breast cancer. Hum Pathol. 2003;34:1001-1008.
14. Lopez-Bonet E, Alonso-Ruano M, Barraza G, Vazquez-Martin A, Bernado L, Menendez JA. Solid neuroendocrine breast carcinomas: incidence, clinico-pathological features and immunohistochemical profiling. Oncol Rep. 2008;20:1369-1374.
15. Bigotti G, Coli A, Butti A, del Vecchio M, Tartaglione R, Massi G. Primary small cell neuroendocrine carcinoma of the breast. J Exp Clin Cancer Res. 2004;23:691-696.
16. Shin SJ, DeLellis RA, Rosen PP. Small cell carcinoma of the breast - additional immunohistochemical studies. Am J Surg Pathol. 2001;25:831-832.
17. Surveillance, Epidemiology, and End Results. Vol 2009. Bethesda, MD: National Cancer Institute; 2009.
18. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007;25:118-145.
19. Greene FL, Page DL, Fleming ID, et al, eds. AJCC Cancer Staging Manual. 6th ed. New York, NY: Springer-Verlag; 2002: 223-228.
20. Therneau TM, Grambsch PM. The Cox model. In: Therneau TM, Grambsch PM, eds. Modeling Survival Data: Extending the Cox Model. New York, NY: Springer; 2001: 39-78.
21. van Krimpen C, Elferink A, Broodman CA, Hop WC, Pronk A, Menke M. The prognostic influence of neuroendocrine differentiation in breast cancer: results of a long-term follow-up study. Breast. 2004;13:329-333.
22. Nassar H, Qureshi H, Volkanadsay N, Visscher D. Clinicopathologic analysis of solid papillary carcinoma of the breast and associated invasive carcinomas. Am J Surg Pathol. 2006;30:501-507.
23. Yao JC, Hassan M, Phan A, et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26:3063-3072.
24. Weigelt B, Geyer FC, Horlings HM, Kreike B, Halfwerk H, Reis-Filho JS. Mucinous and neuroendocrine breast carcinomas are transcriptionally distinct from invasive ductal carcinomas of no special type. Mod Pathol. 2009;22:1401-1414.